Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome

2020171 citationsJournal Articlegold Open Access

Authors

María Orietta Borghi · IRCCS Istituto Auxologico Italiano

Asmaa Beltagy · Alexandria University

Emirena Garrafa · University of Brescia

Daniele Curreli · Istituti di Ricovero e Cura a Carattere Scientifico

Germana Cecchini · Istituti di Ricovero e Cura a Carattere Scientifico

Caterina Bodio · Istituti di Ricovero e Cura a Carattere Scientifico

C. Grossi

Abstract

aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β<sub>2</sub>GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.

Topics & Keywords

COVID-19 Clinical Research Studies Diabetes and associated disorders Erythrocyte Function and Pathophysiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Frontiers in Immunology

Volume 11, pp. 584241-584241

DOI: 10.3389/fimmu.2020.584241

Field-Weighted Citation Impact: 3.78